Jing Wang1, Zong-Lang Lai1,2, Xin-Yi Chen1, Dong-Yun Li1, Ya-Yue Zhang1, Wei Ma1, Yu-Ting Chu1, Feng-Qin Shi1, Lu Yang1, Li Hou3. 1. Department of Oncology and Hematology, Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine, Beijing, 100700, China. 2. Department of Oncology, Chongqing Hospital of Traditional Chinese Medicine, Chongqing, 400021, China. 3. Department of Oncology and Hematology, Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine, Beijing, 100700, China. houli1203@126.com.
Abstract
OBJECTIVE: To observe the effects of Compound Zhebei Granule (, CZBG) combined with chemotherapy on surface markers of leukemia stem cell (LSC) in the bone marrow of patients with acute myeloid leukemia (AML). METHODS: Seventy-eight patients with AML received bone marrow aspiration and the percentages of CD34(+) CD123(+) and CD33(+) CD123(+) cells were tested using flow cytometry method. A total of 24 refractory or relapsed AML patients were enrolled and treated with one cycle of standard chemotherapy combined with CZBG. Bone marrow samples were obtained before and after treatment, and the percentages of CD34(+) CD123(+) and CD33(+) CD123(+) cells were examined by flflow cytometry. RESULTS: Compared with refractory or relapsed AML patients, patients achieved remission had a significant lower percentage of CD34(+) CD123(+) cells(P<0.01) and CD33(+) CD123(+) cells (P<0.01), indicating that controlling the LSC percentage may be important for patients with AML to achieve sustainable remission. Compared with those before treatment, the expression levels of CD34(+) CD123(+) were significantly decreased after CZBG combined with chemotherapy treatment (P<0.01). The percentages of CD34(+) CD123(+) cells and CD33(+) CD123(+) in patients achieving complete remission after CZBG combined with chemotherapy treatment were both significantly lower than those in patients with nonremission (P<0.01). CONCLUSION: CZBG combining chemotherapy could reduce the percentages of CD34(+) CD123(+) and CD33(+) CD123(+) LSC, which might improve the clinical efficacy of refractory or relapsed AML.
OBJECTIVE: To observe the effects of Compound Zhebei Granule (, CZBG) combined with chemotherapy on surface markers of leukemia stem cell (LSC) in the bone marrow of patients with acute myeloid leukemia (AML). METHODS: Seventy-eight patients with AML received bone marrow aspiration and the percentages of CD34(+) CD123(+) and CD33(+) CD123(+) cells were tested using flow cytometry method. A total of 24 refractory or relapsed AMLpatients were enrolled and treated with one cycle of standard chemotherapy combined with CZBG. Bone marrow samples were obtained before and after treatment, and the percentages of CD34(+) CD123(+) and CD33(+) CD123(+) cells were examined by flflow cytometry. RESULTS: Compared with refractory or relapsed AMLpatients, patients achieved remission had a significant lower percentage of CD34(+) CD123(+) cells(P<0.01) and CD33(+) CD123(+) cells (P<0.01), indicating that controlling the LSC percentage may be important for patients with AML to achieve sustainable remission. Compared with those before treatment, the expression levels of CD34(+) CD123(+) were significantly decreased after CZBG combined with chemotherapy treatment (P<0.01). The percentages of CD34(+) CD123(+) cells and CD33(+) CD123(+) in patients achieving complete remission after CZBG combined with chemotherapy treatment were both significantly lower than those in patients with nonremission (P<0.01). CONCLUSION:CZBG combining chemotherapy could reduce the percentages of CD34(+) CD123(+) and CD33(+) CD123(+) LSC, which might improve the clinical efficacy of refractory or relapsed AML.
Authors: C T Jordan; D Upchurch; S J Szilvassy; M L Guzman; D S Howard; A L Pettigrew; T Meyerrose; R Rossi; B Grimes; D A Rizzieri; S M Luger; G L Phillips Journal: Leukemia Date: 2000-10 Impact factor: 11.528
Authors: T Lapidot; C Sirard; J Vormoor; B Murdoch; T Hoang; J Caceres-Cortes; M Minden; B Paterson; M A Caligiuri; J E Dick Journal: Nature Date: 1994-02-17 Impact factor: 49.962
Authors: Monica L Guzman; Randall M Rossi; Sundar Neelakantan; Xiaojie Li; Cheryl A Corbett; Duane C Hassane; Michael W Becker; John M Bennett; Edmund Sullivan; Joshua L Lachowicz; Andrew Vaughan; Christopher J Sweeney; William Matthews; Martin Carroll; Jane L Liesveld; Peter A Crooks; Craig T Jordan Journal: Blood Date: 2007-09-05 Impact factor: 22.113
Authors: Liqing Jin; Erwin M Lee; Hayley S Ramshaw; Samantha J Busfield; Armando G Peoppl; Lucy Wilkinson; Mark A Guthridge; Daniel Thomas; Emma F Barry; Andrew Boyd; David P Gearing; Gino Vairo; Angel F Lopez; John E Dick; Richard B Lock Journal: Cell Stem Cell Date: 2009-07-02 Impact factor: 24.633
Authors: Igor Valentim Barreto; Flávia Melo Cunha de Pinho Pessoa; Caio Bezerra Machado; Laudreísa da Costa Pantoja; Rodrigo Monteiro Ribeiro; Germison Silva Lopes; Maria Elisabete Amaral de Moraes; Manoel Odorico de Moraes Filho; Lucas Eduardo Botelho de Souza; Rommel Mário Rodriguez Burbano; André Salim Khayat; Caroline Aquino Moreira-Nunes Journal: Front Oncol Date: 2022-06-24 Impact factor: 5.738